Philippe Armand, MD

Checkpoint Inhibitors in Lymphoma: A New Universe

February 2016, Vol. 5, No. 1 - ASH 2015, ASH Highlights

Immunotherapy is generating great excitement in melanoma and non–small cell lung cancer (NSCLC). FDA approvals of checkpoint inhibitors in these tumor types, as well as encouraging preliminary results in other solid tumors, have paved the way for studying them in hematologic cancers.Philippe Armand, MD, Dana-Farber Cancer Institute, Boston, MA, discussed [ Read More ]